Aligos Therapeutics to Present Multiple Posters During The Liver Meeting® 2019
SOUTH SAN FRANCISCO, Calif. October 29, 2019 – Aligos Therapeutics, Inc. (Aligos), a pre-clinical stage biotechnology company focused on the development of targeted therapies for hepatologic diseases and viral infections, including chronic hepatitis B (CHB), nonalcoholic steatohepatitis (NASH), and hepatocellular carcinoma (HCC), today announced the upcoming presentation of four abstracts at The Liver Meeting® hosted annually by the American Association for the Study of Liver Disease (AASLD). The 2019 meeting will be held in Boston on November 8-12.
Experts from Aligos’ team of scientists will present posters detailing recent advances in the company’s products in development to address CHB and NASH. Poster presentation details include the following:
Poster session I
Date/Time: Friday, November 8, 12:30 p.m. – 1:30p.m. ET
Location: John B. Hynes Memorial Convention Center
- Poster Title: S-Antigen Transport-inhibiting Oligonucleotide Polymers (STOPs) can Effectively Inhibit Hepatitis B Surface Antigen (HBsAg) Secretion from Hepatitis B Virus (HBV) Cell Lines
Poster number: 689
Presenter: Jin Hong (Director, Oligonucleotide Biology)
- Poster Title: Preclinical Assessment of a Novel Capsid Assembly Modulator, ALG-001075, Demonstrates Best-in-Class In Vitro Potency and In Vivo Antiviral Efficacy
Poster number: 699
Presenter: Yannick Debing (Senior Scientist)
- Poster Title: Preclinical Assessment of Potency and Efficacy of a Novel Class-II Capsid Assembly Modulator ALG-001024
Poster number: 703
Presenter: Andreas Jekle (Director, Virology)
Poster session IV
Date/Time: Monday, November 11, 12:30 p.m. – 1:30 p.m. ET
Location: John B. Hynes Memorial Convention Center
- Poster Title: Preclinical development of ALG-009 as a Potent and Selective Thyroid Hormone Receptor Beta Agonist for the Treatment of NASH
Poster number: 2149
Presenter: Jerome Deval (Director, Biochemistry)
